Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rMenB + OMV + MenACWY vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The rMenB + OMV + MenACWY vaccine is an investigational multicomponent combination vaccine designed to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, B, C, W, and Y. Developed by Novartis Vaccines (now part of GSK), the formulation integrates the components of the licensed serogroup B vaccine (Bexsero) — including recombinant proteins NHBA, NadA, and fHbp, along with outer membrane vesicles (OMV) — with the quadrivalent MenACWY-CRM conjugate vaccine (Menveo). The vaccine is formulated with an aluminum hydroxide adjuvant and administered via intramuscular injection. It was evaluated in Phase 2 clinical trials (such as NCT01210885) to assess the safety and immunogenicity of various combined formulations in adolescents, aiming to provide broad-spectrum protection against the five major disease-causing serogroups in a single immunization series.
- Other names
- MenABCWY vaccinerMenB+OMV-MenACWY-CRMNovartis MenABCWY vaccine
02
Targets
PorB (Major outer membrane porin PorB)fHbp (Factor H-binding protein)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideHS (Heparan sulfate)NHBA (Neisserial heparin-binding antigen)NadA (Neisserial adhesin A)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)LOS (Lipooligosaccharide)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)CFH (Complement factor H)PorA (Major outer membrane protein PorA)
Beyond the preview
Go deeper on rMenB + OMV + MenACWY vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rMenB + OMV + MenACWY vaccine.